Cyclerion Therapeutics, Inc. (CYCN)Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
3.79 USD
-0.20
(-5.013%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.79 |
Hot Take ↕ | Aug. 22, 2026, 2:52 a.m. EDT
The immediate outlook is neutral due to a sharp, volatile price rally that has erased much of the historical discount, yet the underlying business fundamentals remain catastrophic. The company has endured six consecutive years of declining annual returns, with the stock trading at a fraction of its 2019 value despite a recent surge in volume and news regarding potential mergers and collaborations. This rally appears to be a speculative reaction to partnership announcements rather than a reversal of the company's deteriorating financial reality, evidenced by negative operating cash flow, negative equity, and a forward P/E that implies no earnings. With no dividend history and a balance sheet showing significant distress, the investment case relies entirely on the success of future strategic deals rather than organic business recovery, making it unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.068835 |
| MSTL | 0.072623 |
| AutoTheta | 0.106014 |
| MSTL_70 | 0.120857 |
| AutoARIMA | 0.138066 |
| MSTL_115 | 0.160955 |
| MSTL_70_115 | 0.165316 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 10.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.181 |
| Excess Kurtosis | -1.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.49 |
| Market Cap | 16,411,890 |
| Forward P/E | -2.89 |
| Beta | 1.75 |
| Website | https://www.cyclerion.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.58964145 |
| Address1 | 245 First Street, Riverview II |
| Address2 | 18th Floor |
| All Time High | 457.0 |
| All Time Low | 1.027 |
| Ask | 4.94 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 57,760 |
| Average Daily Volume3 Month | 31,053 |
| Average Volume | 31,053 |
| Average Volume10Days | 57,760 |
| Beta | 1.747 |
| Bid | 2.86 |
| Bid Size | 2 |
| Book Value | 1.195 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.79 |
| Current Ratio | 0.821 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.27 |
| Day Low | 3.76 |
| Display Name | Cyclerion Therapeutics |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,397,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 8.458 |
| Enterprise Value | 16,070,747 |
| Eps Forward | -1.31 |
| Eps Trailing Twelve Months | -1.57 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.6248 |
| Fifty Day Average Change | 0.1652 |
| Fifty Day Average Change Percent | 0.045574926 |
| Fifty Two Week Change Percent | 58.964146 |
| Fifty Two Week High | 8.48 |
| Fifty Two Week High Change | -4.6899996 |
| Fifty Two Week High Change Percent | -0.553066 |
| Fifty Two Week Low | 1.027 |
| Fifty Two Week Low Change | 2.763 |
| Fifty Two Week Low Change Percent | 2.6903603 |
| Fifty Two Week Range | 1.027 - 8.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,552,915,800,000 |
| Float Shares | 1,176,203 |
| Forward Eps | -1.31 |
| Forward P E | -2.8931298 |
| Free Cashflow | -2,075,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Fullday Change | -0.2 |
| Fullday Change Percent | -5.01253 |
| Fullday Price | 3.79 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.15946999 |
| Gross Profits | 303,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21704 |
| Held Percent Institutions | 0.70861 |
| Implied Shares Outstanding | 4,330,314 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,684,195,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Cyclerion Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 16,411,890 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_561493203 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -6,707,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 18,584,963 |
| Number Of Analyst Opinions | 1 |
| Open | 3.99 |
| Operating Cashflow | -4,451,000 |
| Operating Margins | -3.59158 |
| Payout Ratio | 0.0 |
| Phone | 857 327 8778 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.79 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 3.99 |
| Price Hint | 4 |
| Price To Book | 3.171548 |
| Price To Sales Trailing12 Months | 8.637836 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.755 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.2 |
| Regular Market Change Percent | -5.01253 |
| Regular Market Day High | 4.27 |
| Regular Market Day Low | 3.76 |
| Regular Market Day Range | 3.76 - 4.27 |
| Regular Market Open | 3.99 |
| Regular Market Previous Close | 3.99 |
| Regular Market Price | 3.79 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 60,010 |
| Return On Assets | -0.52331 |
| Return On Equity | -0.98221 |
| Revenue Per Share | 0.49 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,330,314 |
| Shares Percent Shares Out | 0.0112 |
| Shares Short | 52,394 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 34,811 |
| Short Name | Cyclerion Therapeutics, Inc. |
| Short Percent Of Float | 0.013300001 |
| Short Ratio | 2.2 |
| Source Interval | 15 |
| State | MA |
| Symbol | CYCN |
| Target High Price | 8.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 8.0 |
| Target Median Price | 8.0 |
| Total Cash | 1,391,000 |
| Total Cash Per Share | 0.302 |
| Total Debt | 0 |
| Total Revenue | 1,900,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.469025 |
| Two Hundred Day Average Change | 1.3209751 |
| Two Hundred Day Average Change Percent | 0.5350189 |
| Type Disp | Equity |
| Volume | 60,010 |
| Website | https://www.cyclerion.com |
| Zip | 2,142 |